Shandong Weigao Group Medical Polymer Management
Management criteria checks 2/4
Shandong Weigao Group Medical Polymer's CEO is Rinan Cong, appointed in Mar 2021, has a tenure of 3.17 years. total yearly compensation is CN¥4.96M, comprised of 19.2% salary and 80.8% bonuses, including company stock and options. directly owns 0.048% of the company’s shares, worth HK$11.75M. The average tenure of the management team and the board of directors is 5.2 years and 2.1 years respectively.
Key information
Rinan Cong
Chief executive officer
CN¥5.0m
Total compensation
| CEO salary percentage | 19.2% |
| CEO tenure | 3.2yrs |
| CEO ownership | 0.05% |
| Management average tenure | 5.2yrs |
| Board average tenure | 2.1yrs |
Recent management updates
Recent updates
Earnings Not Telling The Story For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)
Apr 23
Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results
Mar 28Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Shares May Have Run Too Fast Too Soon
Jan 09Returns On Capital Are Showing Encouraging Signs At Shandong Weigao Group Medical Polymer (HKG:1066)
Dec 22Are Investors Undervaluing Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) By 44%?
Nov 10Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?
Oct 05Return Trends At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Appealing
Aug 01Is Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Trading At A 28% Discount?
Jul 19Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth
Jun 22Is Shandong Weigao Group Medical Polymer (HKG:1066) Using Too Much Debt?
Jun 09The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing
Apr 27Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth
Mar 17A Look At The Intrinsic Value Of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)
Feb 27Returns On Capital At Shandong Weigao Group Medical Polymer (HKG:1066) Have Hit The Brakes
Jan 18Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?
Dec 12Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Shares Could Be 21% Below Their Intrinsic Value Estimate
Nov 29Here's Why We Think Shandong Weigao Group Medical Polymer (HKG:1066) Might Deserve Your Attention Today
Nov 14Shandong Weigao Group Medical Polymer (HKG:1066) Is Paying Out A Larger Dividend Than Last Year
Oct 03The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing
Sep 21Shandong Weigao Group Medical Polymer (HKG:1066) Could Easily Take On More Debt
Sep 05Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Intrinsic Value Is Potentially 27% Above Its Share Price
Aug 23Here's Why Shandong Weigao Group Medical Polymer (HKG:1066) Has Caught The Eye Of Investors
Aug 08There's Been No Shortage Of Growth Recently For Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital
Jun 22Shandong Weigao Group Medical Polymer (HKG:1066) Will Pay A Smaller Dividend Than Last Year
Jun 08An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 27% Undervalued
May 16Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?
May 03Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital Are Heading Higher
Mar 17Is There An Opportunity With Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 42% Undervaluation?
Jan 28Does Shandong Weigao Group Medical Polymer (HKG:1066) Deserve A Spot On Your Watchlist?
Jan 13Returns Are Gaining Momentum At Shandong Weigao Group Medical Polymer (HKG:1066)
Dec 17Shandong Weigao Group Medical Polymer (HKG:1066) Seems To Use Debt Rather Sparingly
Dec 05An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 32% Undervalued
Oct 18Do Shandong Weigao Group Medical Polymer's (HKG:1066) Earnings Warrant Your Attention?
Oct 06Shandong Weigao Group Medical Polymer (HKG:1066) Shareholders Will Want The ROCE Trajectory To Continue
Sep 10Shandong Weigao Group Medical Polymer (HKG:1066) Has A Rock Solid Balance Sheet
Aug 29Calculating The Fair Value Of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)
Jul 09Here's Why I Think Shandong Weigao Group Medical Polymer (HKG:1066) Might Deserve Your Attention Today
Jun 26Investors Met With Slowing Returns on Capital At Shandong Weigao Group Medical Polymer (HKG:1066)
Jun 02These 4 Measures Indicate That Shandong Weigao Group Medical Polymer (HKG:1066) Is Using Debt Reasonably Well
Apr 24Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Shares Could Be 49% Below Their Intrinsic Value Estimate
Mar 31Here's What Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Shareholder Ownership Structure Looks Like
Mar 11The Trends At Shandong Weigao Group Medical Polymer (HKG:1066) That You Should Know About
Feb 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | CN¥2b |
| Sep 30 2023 | n/a | n/a | CN¥2b |
| Jun 30 2023 | n/a | n/a | CN¥2b |
| Mar 31 2023 | n/a | n/a | CN¥3b |
| Dec 31 2022 | CN¥5m | CN¥950k | CN¥3b |
| Sep 30 2022 | n/a | n/a | CN¥3b |
| Jun 30 2022 | n/a | n/a | CN¥3b |
| Mar 31 2022 | n/a | n/a | CN¥2b |
| Dec 31 2021 | CN¥3m | CN¥903k | CN¥2b |
Compensation vs Market: Rinan's total compensation ($USD684.30K) is about average for companies of similar size in the Hong Kong market ($USD575.41K).
Compensation vs Earnings: Rinan's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Rinan Cong (42 yo)
3.2yrs
Tenure
CN¥4,955,000
Compensation
Mr. Rinan Cong serves as Chief Executive Officer at Shandong Weigao Group Medical Polymer Company Limited since March 30, 2021 and serves as Executive Director since May 24, 2021. He joined the Company in...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board & Compliance Officer | 3.2yrs | CN¥12.09m | 0.14% CN¥ 34.6m | |
| CEO & Executive Director | 3.2yrs | CN¥4.96m | 0.048% CN¥ 11.7m | |
| Executive Director | 1.9yrs | CN¥1.56m | no data | |
| Chief Financial Officer | 7.3yrs | no data | no data | |
| Company Secretary | 18yrs | no data | no data |
5.2yrs
Average Tenure
48yo
Average Age
Experienced Management: 1066's management team is seasoned and experienced (5.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board & Compliance Officer | 3.2yrs | CN¥12.09m | 0.14% CN¥ 34.6m | |
| CEO & Executive Director | 3yrs | CN¥4.96m | 0.048% CN¥ 11.7m | |
| Executive Director | 1.9yrs | CN¥1.56m | no data | |
| Non-Executive Director | 3.2yrs | no data | no data | |
| Independent Non-Executive Director | 1.7yrs | CN¥30.00k | no data | |
| Independent Non-Executive Director | 1.9yrs | CN¥97.00k | no data | |
| Vice Chairman | 3.2yrs | no data | no data | |
| Chairman of the Supervisors | 3.8yrs | no data | no data | |
| Shareholders Representative Supervisor | 1.9yrs | no data | no data | |
| Employee Representative Supervisor | 2.1yrs | no data | no data | |
| Independent Non-Executive Director | 1.4yrs | no data | no data |
2.1yrs
Average Tenure
47yo
Average Age
Experienced Board: 1066's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.